Case of a patient with heart failure, dilated cardiomyopathy and atrial fibrillation treated with sacubitril/valsartan
Authors:
- 20 March 2019
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 35 (sup3) , 19-22
Abstract
A novel combination consisting of the neprilysin inhibitor, sacubitril, and the angiotensin-receptor blocker, valsartan (belonging to the newly established class of angiotensin receptor/neprilysin inhibitors), was shown to be effective in the treatment of heart failure (HF) by improving patient clinical status, and reducing re-hospitalization rate and mortality. We report a case of a 29 year old male with HF, dilated cardiomyopathy possibly related to myocarditis and atrial fibrillation with reduced ejection fraction. Sacubitril/valsartan treatment was initiated after two years of standard treatment. In two years, therapy with sacubitril/valsartan led to persistence in sinus rhythm, progressive recovery of ejection fraction, functionality and reduction of cardiac volumes. The patient is currently in good condition and has suspended diuretic therapy in the last six months.Keywords
Funding Information
- Novartis Farma
This publication has 5 references indexed in Scilit:
- Advanced heart failure: an appraisal of the potential of levosimendan in this end-stage scenario and some related ethical considerationsExpert Review of Cardiovascular Therapy, 2016
- 2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart FailureEuropean Journal of Heart Failure, 2016
- Current state-of-the-art of device therapy for advanced heart failureCroatian Medical Journal, 2014
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureNew England Journal of Medicine, 2014
- Smart polymers for peptide and protein parenteral sustained deliveryDrug Discovery Today: Technologies, 2012